文献速递湿疹皮炎与荨麻疹

儿童特应性皮炎患者的治疗模式:基于保险索赔数据的分析

Treatment patterns of pediatric patients with atopic dermatitis: A claims data analysis.
PubMed 文献 · J Am Acad Dermatol · 2019-08-07

结果显示78.6%患者被处方至少一种AD药物,86.7%使用外用糖皮质激素,24.4%使用系统性糖皮质激素,且系统免疫抑制剂使用极少(<0.5%)。系统性糖皮质激素和其他在AD中疗效未经证实的药物被频繁处方,提示需要更安全有效的替代方案。

要点

  • 78.6%儿童AD患者被处方至少一种AD药物,86.7%使用外用糖皮质激素。
  • 24.4%患者使用系统性糖皮质激素,其中51.8%无哮喘或过敏性共病。
  • 系统免疫抑制剂使用极少(<0.5%),专科医生更倾向处方高效价外用药或系统治疗。

核心结论

  • 系统性糖皮质激素尽管已知风险,以及在AD中疗效未经证实的其他药物,被频繁处方,提示需要更安全有效的替代方案。

主要发现

  • 78.6%患者被处方至少一种AD药物;86.7%使用外用糖皮质激素,5.4%使用钙调神经磷酸酶抑制剂。
  • 24.4%患者使用系统性糖皮质激素,其中51.8%无哮喘或过敏性共病。
  • 46.6%患者使用抗组胺药,其中62.0%无哮喘或过敏性共病;16.2%使用孟鲁司特,其中41.3%无哮喘或过敏性共病。
  • 系统免疫抑制剂使用极少(<0.5%)。
  • 高效价外用糖皮质激素和系统性糖皮质激素的使用随年龄增长而增加;专科医生更可能处方高效价外用药和/或系统治疗,无论患者年龄;少数患者由专科医生治疗或转诊。

临床怎么用

  • 临床应关注儿童AD患者系统性糖皮质激素的频繁使用,尤其对于无哮喘或过敏性共病的患者,需评估风险获益并考虑更安全的替代方案。
  • 专科医生更倾向处方高效价外用药或系统治疗,但少数患者由专科医生治疗或转诊,提示可能需要加强专科转诊和规范化治疗。

局限性

  • AD患者识别依赖于账单诊断;疾病严重程度通过处方治疗来代理评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-world evidence on treatment patterns of pediatric patients with atopic dermatitis (AD) is sparse. OBJECTIVE: To assess current treatment patterns in pediatric AD patients. METHODS: Retrospective observational analysis of commercial insurance and Medicaid administrative claims data (January 2011-December 2016) for pediatric AD patients, stratified by age and provider type. RESULTS: The analytic sample comprised 607,258 pediatric AD patients. Median observation period was 30.3 months. Overall, 78.6% were prescribed ≥1 AD medication; 86.7% were prescribed topical corticosteroids, and 5.4% were prescribed a calcineurin inhibitor. Systemic corticosteroids (SCSs) were prescribed for 24.4% of patients, 51.8% of whom did not have asthma or allergic comorbidities. Of the 46.6% prescribed an antihistamine and 16.2% prescribed montelukast, 62.0% and 41.3%, respectively, did not have asthma or allergic comorbidities. Systemic immunosuppressants were rarely prescribed (<0.5%). Higher potency topical corticosteroid and SCS use increased with age. Treatment patterns varied by provider type; specialists were more likely to prescribe higher potency topicals and/or systemics, regardless of patient age. A minority of patients were treated by or referred to a specialist. LIMITATIONS: Identification of AD patients relied on billing diagnoses; the disease severity was proxied by the treatment prescribed. CONCLUSION: Results indicate that SCSs, despite known risks, and other medications with disproven efficacy in AD are frequently prescribed, suggesting a need for safer and more effective alternatives.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Paller AS, Siegfried EC, Vekeman F, et al. Treatment patterns of pediatric patients with atopic dermatitis: A claims data analysis. J Am Acad Dermatol. 2019. PMID: 31400453. doi:10.1016/j.jaad.2019.07.105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。